Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Flutamide

FDA-approved product (capsule, oral), marketed as Eulexin, Flutamide.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Flutamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Carcinoma
  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anti-androgens
FDA pharmacologic class
Androgen Receptor Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA35.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli13.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Flutamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Flutamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCC

    NCT06694350 · start 2024-12

    Registered record
    Registry ID
    NCT06694350
    Conditions
    Head and Neck Squamous Cell Carcinoma
    Interventions
    Pembrolizumab+Flutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-12
    Completion
    2027-12
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Squamous Cell Carcinoma
    InterventionPembrolizumab+Flutamide
    PhasePhase 2
    Registry statusNot yet recruiting

  • Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT

    NCT05983198 · start 2023-11-07

    Registered record
    Registry ID
    NCT05983198
    Conditions
    Prostate Cancer
    Interventions
    225Ac-PSMA-R2; 68Ga-PSMA-R2; 68Ga-PSMA-11
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2023-11-07
    Completion
    2031-03-04
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention225Ac-PSMA-R2; 68Ga-PSMA-R2; 68Ga-PSMA-11
    PhasePhase 1
    Registry statusActive not recruiting

  • Contributions to Hypertension With Androgen Deprivation Therapy

    NCT05700903 · start 2023-09-20

    Registered record
    Registry ID
    NCT05700903
    Conditions
    Androgen Deprivation Therapy; Prostate Cancer; Hypertension; Autonomic Dysfunction; Renal Disease
    Interventions
    Gonadotropin Releasing Hormone Agonists (GNRH); Androgen receptor (AR) inhibitor; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2023-09-20
    Completion
    2025-07-16
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAndrogen Deprivation Therapy; Prostate Cancer; Hypertension; Autonomic Dysfunction +1 more
    InterventionGonadotropin Releasing Hormone Agonists (GNRH); Androgen receptor (AR) inhibitor; Placebo
    PhasePhase 4
    Registry statusTerminated

  • Effect of New Topical Preparation for Treatment of Acne Vulgaris

    NCT05899699 · start 2023-06-05

    Registered record
    Registry ID
    NCT05899699
    Conditions
    Acne Vulgaris
    Interventions
    DAP-FLU ME; Adapalene .1% gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-06-05
    Completion
    2023-10-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionDAP-FLU ME; Adapalene .1% gel
    PhasePhase 2
    Registry statusUnknown

  • Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

    NCT05628363 · start 2023-01-18

    Registered record
    Registry ID
    NCT05628363
    Conditions
    Prostate Cancer; Cancer of the Prostate
    Interventions
    Ethos Varian treatment system; Adaptive stereotactic body radiotherapy; Androgen deprivation therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2023-01-18
    Completion
    2030-07-25
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Cancer of the Prostate
    InterventionEthos Varian treatment system; Adaptive stereotactic body radiotherapy; Androgen deprivation therapy
    PhaseNot applicable
    Registry statusActive not recruiting

  • Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

    NCT05050084 · start 2021-12-06

    Registered record
    Registry ID
    NCT05050084
    Conditions
    Prostate Adenocarcinoma
    Interventions
    Bicalutamide; Buserelin; Darolutamide; Degarelix; Flutamide; Goserelin; Histrelin; Leuprolide; Radiation Therapy; Relugolix; Triptorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-12-06
    Completion
    2031-11-11
    Enrolment
    2,050

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma
    InterventionBicalutamide; Buserelin; Darolutamide; Degarelix +7 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

    NCT04787744 · start 2021-07-01

    Registered record
    Registry ID
    NCT04787744
    Conditions
    Prostate Cancer; Oligometastasis; Oligorecurrence; Recurrent Prostate Cancer; Metastatic Prostate Cancer; De Novo Prostate Cancer
    Interventions
    PET-directed Local Therapy using Surgery; PET-directed Local Therapy using Radiation; Salvage Local Therapy for locally recurrent disease; Goserelin, Histrelin, Leuprolide & Triptorelin; ADT + Nilutamide, Flutamide, & Bicalutamide; Degarelix & Relugolix; ADT + Docetaxel +/- prednisone; ADT + Abiraterone + Prednisone; ADT + Abiraterone + Methylprednisolone; ADT + Apalutamide; ADT + Enzalutamide; Prostate-directed Radiation for De novo oligometastatic prostate cancer
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2021-07-01
    Completion
    2029-03-30
    Enrolment
    464

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Oligometastasis; Oligorecurrence; Recurrent Prostate Cancer +2 more
    InterventionPET-directed Local Therapy using Surgery; PET-directed Local Therapy using Radiation; Salvage Local Therapy for locally recurrent disease; Goserelin, Histrelin, Leuprolide & Triptorelin +8 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

    NCT04513717 · start 2021-01-21

    Registered record
    Registry ID
    NCT04513717
    Conditions
    Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
    Interventions
    Apalutamide; Bicalutamide; Biospecimen Collection; Bone Scan; Buserelin; Computed Tomography; Degarelix; Flutamide; Goserelin; Histrelin; Leuprolide; Magnetic Resonance Elastography; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy; Relugolix; Triptorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-01-21
    Completion
    2038-12-31
    Enrolment
    2,753

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
    InterventionApalutamide; Bicalutamide; Biospecimen Collection; Bone Scan +14 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer

    NCT03488810 · start 2020-03-10

    Registered record
    Registry ID
    NCT03488810
    Conditions
    Prostate Cancer
    Interventions
    Radiation Therapy; Apalutamide; Luteinising Hormone Releasing Hormone analog agonist (LHRHa); Non-steroidal anti-androgen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2020-03-10
    Completion
    2026-06-15
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionRadiation Therapy; Apalutamide; Luteinising Hormone Releasing Hormone analog agonist (LHRHa); Non-steroidal anti-androgen
    PhasePhase 3
    Registry statusWithdrawn

  • Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

    NCT04248621 · start 2020-01-23

    Registered record
    Registry ID
    NCT04248621
    Conditions
    Prostatic Neoplasms
    Interventions
    Leuprorelin; Goserelin; Triptorelin; Degarelix; Bicalutamide; Flutamide; Maximum androgen blockade
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-01-23
    Completion
    2022-12-31
    Enrolment
    164

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    InterventionLeuprorelin; Goserelin; Triptorelin; Degarelix +3 more
    PhasePhase 4
    Registry statusUnknown

  • Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression

    NCT03507608 · start 2019-05-10

    Registered record
    Registry ID
    NCT03507608
    Conditions
    Prostate Cancer
    Interventions
    Flutamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2019-05-10
    Completion
    2025-07-03
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionFlutamide; Placebo
    PhaseEarly phase 1
    Registry statusCompleted

  • Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

    NCT03678025 · start 2018-09-24

    Registered record
    Registry ID
    NCT03678025
    Conditions
    Castration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Abiraterone; Bicalutamide; Degarelix; Docetaxel; Flutamide; Goserelin Acetate; Histrelin Acetate; Leuprolide Acetate; Nilutamide; Orchiectomy; Prednisone; Quality-of-Life Assessment; Radiation Therapy; Radical Prostatectomy; Triptorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2018-09-24
    Completion
    2031-10-01
    Enrolment
    1,273

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8 +1 more
    InterventionAbiraterone; Bicalutamide; Degarelix; Docetaxel +11 more
    PhasePhase 3
    Registry statusRecruiting

  • Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer

    NCT02799706 · start 2017-09-25

    Registered record
    Registry ID
    NCT02799706
    Conditions
    Prostate Cancer
    Interventions
    Degarelix; approved GnRH agonist; Radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2017-09-25
    Completion
    2026-06-30
    Enrolment
    885

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDegarelix; approved GnRH agonist; Radiotherapy
    PhasePhase 3
    Registry statusActive not recruiting

  • Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.

    NCT02346578 · start 2014-12

    Registered record
    Registry ID
    NCT02346578
    Conditions
    Castration-resistant Prostate Cancer
    Interventions
    Enzalutamide; Flutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-12
    Completion
    2019-01-22
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-resistant Prostate Cancer
    InterventionEnzalutamide; Flutamide
    PhasePhase 2
    Registry statusCompleted

  • Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women

    NCT01889199 · start 2013-04

    Registered record
    Registry ID
    NCT01889199
    Conditions
    Polycystic Ovary Syndrome (PCOS)
    Interventions
    Flutamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-04
    Completion
    2023-07-06
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovary Syndrome (PCOS)
    InterventionFlutamide; Placebo
    PhasePhase 2
    Registry statusCompleted